Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Pro Medicus (ASX:PME) Shares Continue To Fly High

The Pro Medicus Limited (ASX:PME) share price keeps going up and up, will it ever stop?

The Pro Medicus Limited (ASX: PME) share price keeps going up and up, will it ever stop?

Pro Medicus is a Melbourne-based software owner and developer, licensing products to large US hospitals and Australian radiology clinics. The company has offices in Richmond, Victoria, Berlin, Germany and in the United States.

The Pro Medicus Share Price Continues To Rise

In early trading the Pro Medicus share price is up another 1.65%. Yesterday the Pro Medicus share price increased by 5%. In 2019 the Pro Medicus share price has just about doubled. It’s gone on a great run so far this year.

Some of the share price run-up is certainly justified with a number of positive announcements in FY19. It won a 7-year deal worth $27 million with Partners Healthcare in the US, it won a $3 million contract extension with a German Government Hospital network and it won a 7-year contract with Duke Health, which is the largest health system in the state of North Carolina.

Obviously, the key to generating returns for shareholders is profit growth. In the recent half year result the healthcare business announced that revenue increased by 59.4% to $25.3 million, underlying profit after tax grew by 79.9% to $9.2 million and reported profit after tax increased by 184.3% to $9.1 million.

Its EBIT margin (click here to learn what EBIT means) increased from 48.5% to 51.8%, which is a great improvement and speaks of the growing profitability of the business.

I also like that Pro Medicus was debt free at the end of December 2018 and had $24.7 million cash.

Is Pro Medicus A Buy Today?

According to Commsec estimates, Pro Medicus is valued at 133 times the 2020 financial year’s estimated earnings.

Pro Medicus has an excellent future, but it has a price to match. Most of the best ASX growth shares are trading expensively. Even so, I would rather buy shares of Altium which is valued 45 times the 2020 financial year’s estimated earnings.

Currently I would rather buy one of the reliable shares in the free report below instead of Pro Medicus at a much more attractive value.

[ls_content_block id=”14945″ para=”paragraphs”]

Disclosure: Jaz owns shares of Altium at the time of writing, but this could change at any time. 

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content